nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Estradiol—osteoporosis	0.256	0.577	CbGbCtD
Naltrexone—ABCB1—Ethinyl Estradiol—osteoporosis	0.0789	0.178	CbGbCtD
Naltrexone—ABCB1—Conjugated Estrogens—osteoporosis	0.0579	0.13	CbGbCtD
Naltrexone—ABCB1—Estradiol—osteoporosis	0.0508	0.115	CbGbCtD
Naltrexone—Paraesthesia—Risedronate—osteoporosis	0.000325	0.0006	CcSEcCtD
Naltrexone—Pruritus—Estropipate—osteoporosis	0.000324	0.000598	CcSEcCtD
Naltrexone—Discomfort—Zoledronate—osteoporosis	0.000324	0.000598	CcSEcCtD
Naltrexone—Asthenia—Alendronate—osteoporosis	0.000324	0.000597	CcSEcCtD
Naltrexone—Hypersensitivity—Ibandronate—osteoporosis	0.000324	0.000597	CcSEcCtD
Naltrexone—Cough—Conjugated Estrogens—osteoporosis	0.000324	0.000597	CcSEcCtD
Naltrexone—Dyspnoea—Risedronate—osteoporosis	0.000323	0.000595	CcSEcCtD
Naltrexone—Convulsion—Conjugated Estrogens—osteoporosis	0.000321	0.000593	CcSEcCtD
Naltrexone—Dry mouth—Zoledronate—osteoporosis	0.000321	0.000592	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000321	0.000591	CcSEcCtD
Naltrexone—Fatigue—Ethinyl Estradiol—osteoporosis	0.00032	0.000591	CcSEcCtD
Naltrexone—Pruritus—Alendronate—osteoporosis	0.000319	0.000589	CcSEcCtD
Naltrexone—Eye disorder—Estradiol—osteoporosis	0.000319	0.000588	CcSEcCtD
Naltrexone—Tinnitus—Estradiol—osteoporosis	0.000318	0.000587	CcSEcCtD
Naltrexone—Constipation—Ethinyl Estradiol—osteoporosis	0.000317	0.000586	CcSEcCtD
Naltrexone—Confusional state—Zoledronate—osteoporosis	0.000317	0.000585	CcSEcCtD
Naltrexone—Hypersensitivity—Calcitriol—osteoporosis	0.000317	0.000584	CcSEcCtD
Naltrexone—Cardiac disorder—Estradiol—osteoporosis	0.000316	0.000584	CcSEcCtD
Naltrexone—Chest pain—Conjugated Estrogens—osteoporosis	0.000316	0.000583	CcSEcCtD
Naltrexone—Arthralgia—Conjugated Estrogens—osteoporosis	0.000316	0.000583	CcSEcCtD
Naltrexone—Myalgia—Conjugated Estrogens—osteoporosis	0.000316	0.000583	CcSEcCtD
Naltrexone—Asthenia—Ibandronate—osteoporosis	0.000315	0.000581	CcSEcCtD
Naltrexone—Anxiety—Conjugated Estrogens—osteoporosis	0.000315	0.00058	CcSEcCtD
Naltrexone—Nausea—Etidronic acid—osteoporosis	0.000314	0.00058	CcSEcCtD
Naltrexone—Anaphylactic shock—Zoledronate—osteoporosis	0.000314	0.00058	CcSEcCtD
Naltrexone—Oedema—Zoledronate—osteoporosis	0.000314	0.00058	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000314	0.000578	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000314	0.000578	CcSEcCtD
Naltrexone—Diarrhoea—Estropipate—osteoporosis	0.000313	0.000578	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Risedronate—osteoporosis	0.000313	0.000577	CcSEcCtD
Naltrexone—Infection—Zoledronate—osteoporosis	0.000312	0.000576	CcSEcCtD
Naltrexone—Fatigue—Risedronate—osteoporosis	0.000312	0.000576	CcSEcCtD
Naltrexone—Insomnia—Pamidronate—osteoporosis	0.000311	0.000574	CcSEcCtD
Naltrexone—Pruritus—Ibandronate—osteoporosis	0.000311	0.000573	CcSEcCtD
Naltrexone—Pain—Risedronate—osteoporosis	0.00031	0.000571	CcSEcCtD
Naltrexone—Constipation—Risedronate—osteoporosis	0.00031	0.000571	CcSEcCtD
Naltrexone—Angiopathy—Estradiol—osteoporosis	0.000309	0.000571	CcSEcCtD
Naltrexone—Shock—Zoledronate—osteoporosis	0.000309	0.000571	CcSEcCtD
Naltrexone—Paraesthesia—Pamidronate—osteoporosis	0.000309	0.00057	CcSEcCtD
Naltrexone—Diarrhoea—Alendronate—osteoporosis	0.000309	0.00057	CcSEcCtD
Naltrexone—Asthenia—Calcitriol—osteoporosis	0.000308	0.000569	CcSEcCtD
Naltrexone—Nervous system disorder—Zoledronate—osteoporosis	0.000308	0.000569	CcSEcCtD
Naltrexone—Immune system disorder—Estradiol—osteoporosis	0.000308	0.000568	CcSEcCtD
Naltrexone—Mediastinal disorder—Estradiol—osteoporosis	0.000307	0.000567	CcSEcCtD
Naltrexone—Dyspnoea—Pamidronate—osteoporosis	0.000307	0.000566	CcSEcCtD
Naltrexone—Tachycardia—Zoledronate—osteoporosis	0.000307	0.000566	CcSEcCtD
Naltrexone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000306	0.000564	CcSEcCtD
Naltrexone—Chills—Estradiol—osteoporosis	0.000306	0.000564	CcSEcCtD
Naltrexone—Somnolence—Pamidronate—osteoporosis	0.000306	0.000564	CcSEcCtD
Naltrexone—Skin disorder—Zoledronate—osteoporosis	0.000305	0.000563	CcSEcCtD
Naltrexone—Pruritus—Calcitriol—osteoporosis	0.000304	0.000561	CcSEcCtD
Naltrexone—Hyperhidrosis—Zoledronate—osteoporosis	0.000304	0.000561	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000304	0.00056	CcSEcCtD
Naltrexone—Diarrhoea—Raloxifene—osteoporosis	0.000304	0.00056	CcSEcCtD
Naltrexone—Dizziness—Estropipate—osteoporosis	0.000303	0.000559	CcSEcCtD
Naltrexone—Oedema—Conjugated Estrogens—osteoporosis	0.000303	0.000558	CcSEcCtD
Naltrexone—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000303	0.000558	CcSEcCtD
Naltrexone—Alopecia—Estradiol—osteoporosis	0.000301	0.000556	CcSEcCtD
Naltrexone—Infection—Conjugated Estrogens—osteoporosis	0.000301	0.000555	CcSEcCtD
Naltrexone—Diarrhoea—Ibandronate—osteoporosis	0.000301	0.000554	CcSEcCtD
Naltrexone—Anorexia—Zoledronate—osteoporosis	0.0003	0.000553	CcSEcCtD
Naltrexone—Decreased appetite—Pamidronate—osteoporosis	0.000299	0.000552	CcSEcCtD
Naltrexone—Mental disorder—Estradiol—osteoporosis	0.000299	0.000551	CcSEcCtD
Naltrexone—Dizziness—Alendronate—osteoporosis	0.000298	0.00055	CcSEcCtD
Naltrexone—Shock—Conjugated Estrogens—osteoporosis	0.000298	0.000549	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000297	0.000548	CcSEcCtD
Naltrexone—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000297	0.000548	CcSEcCtD
Naltrexone—Malnutrition—Estradiol—osteoporosis	0.000297	0.000548	CcSEcCtD
Naltrexone—Fatigue—Pamidronate—osteoporosis	0.000297	0.000547	CcSEcCtD
Naltrexone—Gastrointestinal pain—Risedronate—osteoporosis	0.000296	0.000546	CcSEcCtD
Naltrexone—Tachycardia—Conjugated Estrogens—osteoporosis	0.000295	0.000545	CcSEcCtD
Naltrexone—Urticaria—Ethinyl Estradiol—osteoporosis	0.000295	0.000544	CcSEcCtD
Naltrexone—Constipation—Pamidronate—osteoporosis	0.000294	0.000543	CcSEcCtD
Naltrexone—Pain—Pamidronate—osteoporosis	0.000294	0.000543	CcSEcCtD
Naltrexone—Diarrhoea—Calcitriol—osteoporosis	0.000294	0.000543	CcSEcCtD
Naltrexone—Skin disorder—Conjugated Estrogens—osteoporosis	0.000294	0.000542	CcSEcCtD
Naltrexone—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000293	0.000542	CcSEcCtD
Naltrexone—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000293	0.000542	CcSEcCtD
Naltrexone—Dizziness—Raloxifene—osteoporosis	0.000293	0.000541	CcSEcCtD
Naltrexone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000293	0.00054	CcSEcCtD
Naltrexone—Flatulence—Estradiol—osteoporosis	0.000292	0.00054	CcSEcCtD
Naltrexone—Tension—Estradiol—osteoporosis	0.000291	0.000537	CcSEcCtD
Naltrexone—Vomiting—Estropipate—osteoporosis	0.000291	0.000537	CcSEcCtD
Naltrexone—Dysgeusia—Estradiol—osteoporosis	0.000291	0.000536	CcSEcCtD
Naltrexone—Dizziness—Ibandronate—osteoporosis	0.00029	0.000536	CcSEcCtD
Naltrexone—Rash—Estropipate—osteoporosis	0.000289	0.000533	CcSEcCtD
Naltrexone—Dermatitis—Estropipate—osteoporosis	0.000289	0.000532	CcSEcCtD
Naltrexone—Anorexia—Conjugated Estrogens—osteoporosis	0.000288	0.000532	CcSEcCtD
Naltrexone—Nervousness—Estradiol—osteoporosis	0.000288	0.000532	CcSEcCtD
Naltrexone—Urticaria—Risedronate—osteoporosis	0.000288	0.000531	CcSEcCtD
Naltrexone—Back pain—Estradiol—osteoporosis	0.000287	0.00053	CcSEcCtD
Naltrexone—Headache—Estropipate—osteoporosis	0.000287	0.000529	CcSEcCtD
Naltrexone—Vomiting—Alendronate—osteoporosis	0.000287	0.000529	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000286	0.000528	CcSEcCtD
Naltrexone—Abdominal pain—Risedronate—osteoporosis	0.000286	0.000528	CcSEcCtD
Naltrexone—Body temperature increased—Risedronate—osteoporosis	0.000286	0.000528	CcSEcCtD
Naltrexone—Muscle spasms—Estradiol—osteoporosis	0.000285	0.000526	CcSEcCtD
Naltrexone—Rash—Alendronate—osteoporosis	0.000284	0.000525	CcSEcCtD
Naltrexone—Insomnia—Zoledronate—osteoporosis	0.000284	0.000525	CcSEcCtD
Naltrexone—Dermatitis—Alendronate—osteoporosis	0.000284	0.000524	CcSEcCtD
Naltrexone—Feeling abnormal—Pamidronate—osteoporosis	0.000284	0.000523	CcSEcCtD
Naltrexone—Headache—Alendronate—osteoporosis	0.000283	0.000521	CcSEcCtD
Naltrexone—Paraesthesia—Zoledronate—osteoporosis	0.000282	0.000521	CcSEcCtD
Naltrexone—Vomiting—Raloxifene—osteoporosis	0.000282	0.00052	CcSEcCtD
Naltrexone—Gastrointestinal pain—Pamidronate—osteoporosis	0.000281	0.000519	CcSEcCtD
Naltrexone—Dyspnoea—Zoledronate—osteoporosis	0.00028	0.000517	CcSEcCtD
Naltrexone—Rash—Raloxifene—osteoporosis	0.00028	0.000516	CcSEcCtD
Naltrexone—Dermatitis—Raloxifene—osteoporosis	0.000279	0.000516	CcSEcCtD
Naltrexone—Somnolence—Zoledronate—osteoporosis	0.000279	0.000516	CcSEcCtD
Naltrexone—Vomiting—Ibandronate—osteoporosis	0.000279	0.000515	CcSEcCtD
Naltrexone—Tremor—Estradiol—osteoporosis	0.000278	0.000513	CcSEcCtD
Naltrexone—Headache—Raloxifene—osteoporosis	0.000278	0.000513	CcSEcCtD
Naltrexone—Rash—Ibandronate—osteoporosis	0.000277	0.000511	CcSEcCtD
Naltrexone—Dermatitis—Ibandronate—osteoporosis	0.000277	0.000511	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000276	0.000509	CcSEcCtD
Naltrexone—Ill-defined disorder—Estradiol—osteoporosis	0.000275	0.000508	CcSEcCtD
Naltrexone—Headache—Ibandronate—osteoporosis	0.000275	0.000508	CcSEcCtD
Naltrexone—Insomnia—Conjugated Estrogens—osteoporosis	0.000274	0.000505	CcSEcCtD
Naltrexone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000274	0.000505	CcSEcCtD
Naltrexone—Vomiting—Calcitriol—osteoporosis	0.000273	0.000504	CcSEcCtD
Naltrexone—Decreased appetite—Zoledronate—osteoporosis	0.000273	0.000504	CcSEcCtD
Naltrexone—Agitation—Estradiol—osteoporosis	0.000273	0.000503	CcSEcCtD
Naltrexone—Nausea—Estropipate—osteoporosis	0.000272	0.000502	CcSEcCtD
Naltrexone—Abdominal pain—Pamidronate—osteoporosis	0.000272	0.000502	CcSEcCtD
Naltrexone—Body temperature increased—Pamidronate—osteoporosis	0.000272	0.000502	CcSEcCtD
Naltrexone—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000272	0.000501	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000271	0.000501	CcSEcCtD
Naltrexone—Angioedema—Estradiol—osteoporosis	0.000271	0.0005	CcSEcCtD
Naltrexone—Rash—Calcitriol—osteoporosis	0.000271	0.0005	CcSEcCtD
Naltrexone—Fatigue—Zoledronate—osteoporosis	0.000271	0.0005	CcSEcCtD
Naltrexone—Dermatitis—Calcitriol—osteoporosis	0.000271	0.0005	CcSEcCtD
Naltrexone—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00027	0.000498	CcSEcCtD
Naltrexone—Headache—Calcitriol—osteoporosis	0.000269	0.000497	CcSEcCtD
Naltrexone—Somnolence—Conjugated Estrogens—osteoporosis	0.000269	0.000496	CcSEcCtD
Naltrexone—Constipation—Zoledronate—osteoporosis	0.000269	0.000496	CcSEcCtD
Naltrexone—Pain—Zoledronate—osteoporosis	0.000269	0.000496	CcSEcCtD
Naltrexone—Nausea—Alendronate—osteoporosis	0.000268	0.000494	CcSEcCtD
Naltrexone—Malaise—Estradiol—osteoporosis	0.000268	0.000494	CcSEcCtD
Naltrexone—Hypersensitivity—Risedronate—osteoporosis	0.000267	0.000492	CcSEcCtD
Naltrexone—Asthenia—Ethinyl Estradiol—osteoporosis	0.000266	0.000491	CcSEcCtD
Naltrexone—Syncope—Estradiol—osteoporosis	0.000266	0.000491	CcSEcCtD
Naltrexone—Nausea—Raloxifene—osteoporosis	0.000264	0.000486	CcSEcCtD
Naltrexone—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000263	0.000485	CcSEcCtD
Naltrexone—Pruritus—Ethinyl Estradiol—osteoporosis	0.000263	0.000485	CcSEcCtD
Naltrexone—Palpitations—Estradiol—osteoporosis	0.000262	0.000484	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000261	0.000482	CcSEcCtD
Naltrexone—Fatigue—Conjugated Estrogens—osteoporosis	0.000261	0.000481	CcSEcCtD
Naltrexone—Nausea—Ibandronate—osteoporosis	0.000261	0.000481	CcSEcCtD
Naltrexone—Loss of consciousness—Estradiol—osteoporosis	0.000261	0.000481	CcSEcCtD
Naltrexone—Asthenia—Risedronate—osteoporosis	0.00026	0.000479	CcSEcCtD
Naltrexone—Feeling abnormal—Zoledronate—osteoporosis	0.000259	0.000478	CcSEcCtD
Naltrexone—Cough—Estradiol—osteoporosis	0.000259	0.000478	CcSEcCtD
Naltrexone—Constipation—Conjugated Estrogens—osteoporosis	0.000259	0.000478	CcSEcCtD
Naltrexone—Pain—Conjugated Estrogens—osteoporosis	0.000259	0.000478	CcSEcCtD
Naltrexone—Gastrointestinal pain—Zoledronate—osteoporosis	0.000257	0.000474	CcSEcCtD
Naltrexone—Hypertension—Estradiol—osteoporosis	0.000256	0.000473	CcSEcCtD
Naltrexone—Pruritus—Risedronate—osteoporosis	0.000256	0.000473	CcSEcCtD
Naltrexone—Nausea—Calcitriol—osteoporosis	0.000255	0.000471	CcSEcCtD
Naltrexone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000254	0.000469	CcSEcCtD
Naltrexone—Hypersensitivity—Pamidronate—osteoporosis	0.000254	0.000468	CcSEcCtD
Naltrexone—Arthralgia—Estradiol—osteoporosis	0.000253	0.000466	CcSEcCtD
Naltrexone—Chest pain—Estradiol—osteoporosis	0.000253	0.000466	CcSEcCtD
Naltrexone—Myalgia—Estradiol—osteoporosis	0.000253	0.000466	CcSEcCtD
Naltrexone—Anxiety—Estradiol—osteoporosis	0.000252	0.000465	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000251	0.000463	CcSEcCtD
Naltrexone—Urticaria—Zoledronate—osteoporosis	0.00025	0.000461	CcSEcCtD
Naltrexone—Discomfort—Estradiol—osteoporosis	0.00025	0.000461	CcSEcCtD
Naltrexone—Abdominal pain—Zoledronate—osteoporosis	0.000248	0.000458	CcSEcCtD
Naltrexone—Body temperature increased—Zoledronate—osteoporosis	0.000248	0.000458	CcSEcCtD
Naltrexone—Diarrhoea—Risedronate—osteoporosis	0.000248	0.000457	CcSEcCtD
Naltrexone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000247	0.000457	CcSEcCtD
Naltrexone—Dry mouth—Estradiol—osteoporosis	0.000247	0.000456	CcSEcCtD
Naltrexone—Asthenia—Pamidronate—osteoporosis	0.000247	0.000456	CcSEcCtD
Naltrexone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000246	0.000453	CcSEcCtD
Naltrexone—Confusional state—Estradiol—osteoporosis	0.000244	0.000451	CcSEcCtD
Naltrexone—Pruritus—Pamidronate—osteoporosis	0.000243	0.000449	CcSEcCtD
Naltrexone—Anaphylactic shock—Estradiol—osteoporosis	0.000242	0.000447	CcSEcCtD
Naltrexone—Oedema—Estradiol—osteoporosis	0.000242	0.000447	CcSEcCtD
Naltrexone—Infection—Estradiol—osteoporosis	0.000241	0.000444	CcSEcCtD
Naltrexone—Urticaria—Conjugated Estrogens—osteoporosis	0.00024	0.000444	CcSEcCtD
Naltrexone—Dizziness—Risedronate—osteoporosis	0.000239	0.000442	CcSEcCtD
Naltrexone—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000239	0.000441	CcSEcCtD
Naltrexone—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000239	0.000441	CcSEcCtD
Naltrexone—Shock—Estradiol—osteoporosis	0.000238	0.00044	CcSEcCtD
Naltrexone—Nervous system disorder—Estradiol—osteoporosis	0.000238	0.000438	CcSEcCtD
Naltrexone—Tachycardia—Estradiol—osteoporosis	0.000236	0.000436	CcSEcCtD
Naltrexone—Vomiting—Ethinyl Estradiol—osteoporosis	0.000236	0.000436	CcSEcCtD
Naltrexone—Diarrhoea—Pamidronate—osteoporosis	0.000235	0.000434	CcSEcCtD
Naltrexone—Skin disorder—Estradiol—osteoporosis	0.000235	0.000434	CcSEcCtD
Naltrexone—Hyperhidrosis—Estradiol—osteoporosis	0.000234	0.000432	CcSEcCtD
Naltrexone—Rash—Ethinyl Estradiol—osteoporosis	0.000234	0.000432	CcSEcCtD
Naltrexone—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000234	0.000432	CcSEcCtD
Naltrexone—Headache—Ethinyl Estradiol—osteoporosis	0.000233	0.000429	CcSEcCtD
Naltrexone—Hypersensitivity—Zoledronate—osteoporosis	0.000232	0.000427	CcSEcCtD
Naltrexone—Vomiting—Risedronate—osteoporosis	0.00023	0.000425	CcSEcCtD
Naltrexone—Rash—Risedronate—osteoporosis	0.000228	0.000421	CcSEcCtD
Naltrexone—Dermatitis—Risedronate—osteoporosis	0.000228	0.000421	CcSEcCtD
Naltrexone—Dizziness—Pamidronate—osteoporosis	0.000228	0.00042	CcSEcCtD
Naltrexone—Headache—Risedronate—osteoporosis	0.000227	0.000418	CcSEcCtD
Naltrexone—Asthenia—Zoledronate—osteoporosis	0.000226	0.000416	CcSEcCtD
Naltrexone—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000223	0.000411	CcSEcCtD
Naltrexone—Pruritus—Zoledronate—osteoporosis	0.000222	0.00041	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000221	0.000407	CcSEcCtD
Naltrexone—Nausea—Ethinyl Estradiol—osteoporosis	0.000221	0.000407	CcSEcCtD
Naltrexone—Insomnia—Estradiol—osteoporosis	0.000219	0.000404	CcSEcCtD
Naltrexone—Vomiting—Pamidronate—osteoporosis	0.000219	0.000404	CcSEcCtD
Naltrexone—Paraesthesia—Estradiol—osteoporosis	0.000218	0.000401	CcSEcCtD
Naltrexone—Asthenia—Conjugated Estrogens—osteoporosis	0.000217	0.000401	CcSEcCtD
Naltrexone—Rash—Pamidronate—osteoporosis	0.000217	0.0004	CcSEcCtD
Naltrexone—Dermatitis—Pamidronate—osteoporosis	0.000217	0.0004	CcSEcCtD
Naltrexone—Dyspnoea—Estradiol—osteoporosis	0.000216	0.000398	CcSEcCtD
Naltrexone—Headache—Pamidronate—osteoporosis	0.000216	0.000398	CcSEcCtD
Naltrexone—Somnolence—Estradiol—osteoporosis	0.000215	0.000397	CcSEcCtD
Naltrexone—Diarrhoea—Zoledronate—osteoporosis	0.000215	0.000397	CcSEcCtD
Naltrexone—Nausea—Risedronate—osteoporosis	0.000215	0.000397	CcSEcCtD
Naltrexone—Pruritus—Conjugated Estrogens—osteoporosis	0.000214	0.000395	CcSEcCtD
Naltrexone—Decreased appetite—Estradiol—osteoporosis	0.000211	0.000389	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Estradiol—osteoporosis	0.000209	0.000386	CcSEcCtD
Naltrexone—Fatigue—Estradiol—osteoporosis	0.000209	0.000385	CcSEcCtD
Naltrexone—Dizziness—Zoledronate—osteoporosis	0.000208	0.000383	CcSEcCtD
Naltrexone—Pain—Estradiol—osteoporosis	0.000207	0.000382	CcSEcCtD
Naltrexone—Constipation—Estradiol—osteoporosis	0.000207	0.000382	CcSEcCtD
Naltrexone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000207	0.000382	CcSEcCtD
Naltrexone—Nausea—Pamidronate—osteoporosis	0.000204	0.000377	CcSEcCtD
Naltrexone—Dizziness—Conjugated Estrogens—osteoporosis	0.0002	0.000369	CcSEcCtD
Naltrexone—Vomiting—Zoledronate—osteoporosis	0.0002	0.000369	CcSEcCtD
Naltrexone—Feeling abnormal—Estradiol—osteoporosis	0.0002	0.000368	CcSEcCtD
Naltrexone—Rash—Zoledronate—osteoporosis	0.000198	0.000366	CcSEcCtD
Naltrexone—Gastrointestinal pain—Estradiol—osteoporosis	0.000198	0.000365	CcSEcCtD
Naltrexone—Dermatitis—Zoledronate—osteoporosis	0.000198	0.000365	CcSEcCtD
Naltrexone—Headache—Zoledronate—osteoporosis	0.000197	0.000363	CcSEcCtD
Naltrexone—Vomiting—Conjugated Estrogens—osteoporosis	0.000192	0.000355	CcSEcCtD
Naltrexone—Urticaria—Estradiol—osteoporosis	0.000192	0.000355	CcSEcCtD
Naltrexone—Abdominal pain—Estradiol—osteoporosis	0.000191	0.000353	CcSEcCtD
Naltrexone—Body temperature increased—Estradiol—osteoporosis	0.000191	0.000353	CcSEcCtD
Naltrexone—Rash—Conjugated Estrogens—osteoporosis	0.000191	0.000352	CcSEcCtD
Naltrexone—Dermatitis—Conjugated Estrogens—osteoporosis	0.000191	0.000352	CcSEcCtD
Naltrexone—Headache—Conjugated Estrogens—osteoporosis	0.00019	0.00035	CcSEcCtD
Naltrexone—Nausea—Zoledronate—osteoporosis	0.000187	0.000344	CcSEcCtD
Naltrexone—Nausea—Conjugated Estrogens—osteoporosis	0.00018	0.000332	CcSEcCtD
Naltrexone—Hypersensitivity—Estradiol—osteoporosis	0.000178	0.000329	CcSEcCtD
Naltrexone—Asthenia—Estradiol—osteoporosis	0.000174	0.000321	CcSEcCtD
Naltrexone—Pruritus—Estradiol—osteoporosis	0.000171	0.000316	CcSEcCtD
Naltrexone—Diarrhoea—Estradiol—osteoporosis	0.000166	0.000306	CcSEcCtD
Naltrexone—Dizziness—Estradiol—osteoporosis	0.00016	0.000296	CcSEcCtD
Naltrexone—Vomiting—Estradiol—osteoporosis	0.000154	0.000284	CcSEcCtD
Naltrexone—Rash—Estradiol—osteoporosis	0.000153	0.000282	CcSEcCtD
Naltrexone—Dermatitis—Estradiol—osteoporosis	0.000153	0.000282	CcSEcCtD
Naltrexone—Headache—Estradiol—osteoporosis	0.000152	0.00028	CcSEcCtD
Naltrexone—Nausea—Estradiol—osteoporosis	0.000144	0.000265	CcSEcCtD
Naltrexone—Naloxone—ESR1—osteoporosis	0.000137	1	CrCbGaD
Naltrexone—OPRK1—Signaling by GPCR—PTH1R—osteoporosis	7.11e-05	0.00511	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—MGLL—osteoporosis	7.1e-05	0.0051	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CNR2—osteoporosis	7.1e-05	0.0051	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—PTHLH—osteoporosis	6.88e-05	0.00494	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—WNT1—osteoporosis	6.67e-05	0.00479	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTH1R—osteoporosis	6.62e-05	0.00476	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CALCR—osteoporosis	6.62e-05	0.00476	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MGLL—osteoporosis	6.45e-05	0.00463	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—ADCY5—osteoporosis	6.24e-05	0.00448	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—MGLL—osteoporosis	6.22e-05	0.00447	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—POMC—osteoporosis	6.21e-05	0.00446	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL1B—osteoporosis	6.2e-05	0.00446	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—PTH—osteoporosis	6.15e-05	0.00442	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CALCA—osteoporosis	6.06e-05	0.00435	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—PTHLH—osteoporosis	6.03e-05	0.00433	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTH1R—osteoporosis	6.01e-05	0.00432	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CALCR—osteoporosis	6.01e-05	0.00432	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CNR2—osteoporosis	6e-05	0.00431	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	5.85e-05	0.0042	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MGLL—osteoporosis	5.65e-05	0.00406	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—WNT1—osteoporosis	5.64e-05	0.00405	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	5.53e-05	0.00397	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—POMC—osteoporosis	5.44e-05	0.00391	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CALCA—osteoporosis	5.31e-05	0.00382	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SOST—osteoporosis	5.3e-05	0.00381	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—ADCY5—osteoporosis	5.27e-05	0.00379	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—MGLL—osteoporosis	5.26e-05	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—POMC—osteoporosis	5.24e-05	0.00376	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—PTHLH—osteoporosis	5.1e-05	0.00366	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—POMC—osteoporosis	5.09e-05	0.00366	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—TGFB1—osteoporosis	4.82e-05	0.00346	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—FDPS—osteoporosis	4.8e-05	0.00345	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PKM—osteoporosis	4.8e-05	0.00345	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALCR—osteoporosis	4.79e-05	0.00344	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTH1R—osteoporosis	4.79e-05	0.00344	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MGLL—osteoporosis	4.78e-05	0.00343	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PTH—osteoporosis	4.69e-05	0.00337	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SOST—osteoporosis	4.65e-05	0.00334	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—POMC—osteoporosis	4.6e-05	0.0033	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—POMC—osteoporosis	4.59e-05	0.0033	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CNR2—osteoporosis	4.57e-05	0.00329	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PGLS—osteoporosis	4.55e-05	0.00327	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPD2—osteoporosis	4.55e-05	0.00327	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CALCA—osteoporosis	4.49e-05	0.00323	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PTH—osteoporosis	4.26e-05	0.00306	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTH1R—osteoporosis	4.2e-05	0.00302	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CALCR—osteoporosis	4.2e-05	0.00302	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ATIC—osteoporosis	4.16e-05	0.00299	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PNP—osteoporosis	4.16e-05	0.00299	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	4.16e-05	0.00299	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CNR2—osteoporosis	4.15e-05	0.00298	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PTH—osteoporosis	4.12e-05	0.00296	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CNR2—osteoporosis	4.01e-05	0.00288	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	3.94e-05	0.00283	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOST—osteoporosis	3.93e-05	0.00282	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—WNT1—osteoporosis	3.9e-05	0.00281	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PTHLH—osteoporosis	3.89e-05	0.00279	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—POMC—osteoporosis	3.88e-05	0.00279	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MGLL—osteoporosis	3.81e-05	0.00274	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTH—osteoporosis	3.74e-05	0.00268	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LRP5—osteoporosis	3.72e-05	0.00267	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	3.69e-05	0.00265	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.65e-05	0.00262	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CNR2—osteoporosis	3.64e-05	0.00262	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—osteoporosis	3.63e-05	0.00261	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LRP6—osteoporosis	3.55e-05	0.00255	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALCR—osteoporosis	3.55e-05	0.00255	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTH1R—osteoporosis	3.55e-05	0.00255	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CA2—osteoporosis	3.54e-05	0.00254	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—OXCT1—osteoporosis	3.54e-05	0.00254	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PTHLH—osteoporosis	3.53e-05	0.00254	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTH—osteoporosis	3.48e-05	0.0025	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MGLL—osteoporosis	3.45e-05	0.00248	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—WNT1—osteoporosis	3.42e-05	0.00246	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CALCA—osteoporosis	3.42e-05	0.00246	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PTHLH—osteoporosis	3.41e-05	0.00245	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CNR2—osteoporosis	3.39e-05	0.00243	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—TGFB1—osteoporosis	3.35e-05	0.00241	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MGLL—osteoporosis	3.34e-05	0.0024	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LRP5—osteoporosis	3.26e-05	0.00234	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL1B—osteoporosis	3.23e-05	0.00232	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—POMC—osteoporosis	3.17e-05	0.00228	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTH—osteoporosis	3.16e-05	0.00227	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LRP6—osteoporosis	3.12e-05	0.00224	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CALCA—osteoporosis	3.11e-05	0.00223	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTHLH—osteoporosis	3.1e-05	0.00222	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	3.09e-05	0.00222	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.08e-05	0.00222	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CNR2—osteoporosis	3.08e-05	0.00221	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CALCA—osteoporosis	3e-05	0.00216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TLN1—osteoporosis	3e-05	0.00216	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—IDH2—osteoporosis	2.93e-05	0.00211	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—WNT1—osteoporosis	2.89e-05	0.00208	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PTHLH—osteoporosis	2.88e-05	0.00207	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MGLL—osteoporosis	2.82e-05	0.00203	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—POMC—osteoporosis	2.78e-05	0.002	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP27A1—osteoporosis	2.76e-05	0.00198	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LRP5—osteoporosis	2.75e-05	0.00198	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CALCA—osteoporosis	2.73e-05	0.00196	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ACP5—osteoporosis	2.68e-05	0.00193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LRP6—osteoporosis	2.63e-05	0.00189	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TLN1—osteoporosis	2.63e-05	0.00189	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTHLH—osteoporosis	2.62e-05	0.00188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—P4HB—osteoporosis	2.59e-05	0.00186	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CALCA—osteoporosis	2.54e-05	0.00182	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTH—osteoporosis	2.52e-05	0.00181	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TGFB1—osteoporosis	2.51e-05	0.0018	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TPI1—osteoporosis	2.49e-05	0.00179	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAP1A—osteoporosis	2.47e-05	0.00178	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CNR2—osteoporosis	2.45e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADCY5—osteoporosis	2.44e-05	0.00175	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFATC1—osteoporosis	2.41e-05	0.00173	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—DKK1—osteoporosis	2.39e-05	0.00172	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	2.39e-05	0.00172	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—POMC—osteoporosis	2.35e-05	0.00169	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—P4HB—osteoporosis	2.35e-05	0.00169	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—osteoporosis	2.34e-05	0.00168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—WNT1—osteoporosis	2.31e-05	0.00166	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CALCA—osteoporosis	2.3e-05	0.00166	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GAPDH—osteoporosis	2.3e-05	0.00165	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—P4HB—osteoporosis	2.27e-05	0.00163	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGA—osteoporosis	2.24e-05	0.00161	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—RAP1A—osteoporosis	2.24e-05	0.00161	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TLN1—osteoporosis	2.22e-05	0.0016	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADCY5—osteoporosis	2.21e-05	0.00159	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTH—osteoporosis	2.21e-05	0.00159	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PKM—osteoporosis	2.2e-05	0.00158	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FDPS—osteoporosis	2.2e-05	0.00158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAP1A—osteoporosis	2.17e-05	0.00156	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CNR2—osteoporosis	2.15e-05	0.00155	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADCY5—osteoporosis	2.14e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFATC1—osteoporosis	2.12e-05	0.00152	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—DKK1—osteoporosis	2.1e-05	0.00151	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PGLS—osteoporosis	2.09e-05	0.0015	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPD2—osteoporosis	2.09e-05	0.0015	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BMP2—osteoporosis	2.09e-05	0.0015	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTHLH—osteoporosis	2.09e-05	0.0015	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.07e-05	0.00148	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGB—osteoporosis	2.04e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—WNT1—osteoporosis	2.02e-05	0.00145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSMA5—osteoporosis	1.97e-05	0.00142	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSMA2—osteoporosis	1.97e-05	0.00142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGA—osteoporosis	1.97e-05	0.00141	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADCY5—osteoporosis	1.94e-05	0.00139	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—P4HB—osteoporosis	1.92e-05	0.00138	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PNP—osteoporosis	1.91e-05	0.00137	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ATIC—osteoporosis	1.91e-05	0.00137	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTH—osteoporosis	1.87e-05	0.00134	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALCA—osteoporosis	1.84e-05	0.00132	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAP1A—osteoporosis	1.83e-05	0.00132	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BMP2—osteoporosis	1.83e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTHLH—osteoporosis	1.83e-05	0.00131	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR2—osteoporosis	1.82e-05	0.00131	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO1—osteoporosis	1.81e-05	0.0013	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADCY5—osteoporosis	1.8e-05	0.0013	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—POMC—osteoporosis	1.79e-05	0.00129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGB—osteoporosis	1.79e-05	0.00129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFATC1—osteoporosis	1.79e-05	0.00129	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSMA2—osteoporosis	1.79e-05	0.00128	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSMA5—osteoporosis	1.79e-05	0.00128	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DKK1—osteoporosis	1.77e-05	0.00127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSMA2—osteoporosis	1.73e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSMA5—osteoporosis	1.73e-05	0.00124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—WNT1—osteoporosis	1.71e-05	0.00123	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KL—osteoporosis	1.67e-05	0.0012	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGA—osteoporosis	1.66e-05	0.00119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADCY5—osteoporosis	1.64e-05	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—POMC—osteoporosis	1.63e-05	0.00117	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA2—osteoporosis	1.62e-05	0.00117	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—OXCT1—osteoporosis	1.62e-05	0.00117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CALCA—osteoporosis	1.61e-05	0.00116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6R—osteoporosis	1.59e-05	0.00114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MGLL—osteoporosis	1.58e-05	0.00114	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—POMC—osteoporosis	1.57e-05	0.00113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BMP2—osteoporosis	1.55e-05	0.00111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTHLH—osteoporosis	1.55e-05	0.00111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGB—osteoporosis	1.51e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KL—osteoporosis	1.46e-05	0.00105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSMA2—osteoporosis	1.46e-05	0.00105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSMA5—osteoporosis	1.46e-05	0.00105	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP19A1—osteoporosis	1.45e-05	0.00104	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—POMC—osteoporosis	1.43e-05	0.00102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6R—osteoporosis	1.39e-05	0.001	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALCA—osteoporosis	1.36e-05	0.000978	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—IDH2—osteoporosis	1.35e-05	0.000967	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—POMC—osteoporosis	1.33e-05	0.000954	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADCY5—osteoporosis	1.31e-05	0.000939	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP27A1—osteoporosis	1.27e-05	0.000909	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SPP1—osteoporosis	1.26e-05	0.000908	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.24e-05	0.000892	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.24e-05	0.00089	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KL—osteoporosis	1.24e-05	0.000888	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACP5—osteoporosis	1.23e-05	0.000884	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—osteoporosis	1.21e-05	0.000866	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADCY5—osteoporosis	1.18e-05	0.000851	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—osteoporosis	1.18e-05	0.000848	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6R—osteoporosis	1.18e-05	0.000845	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.16e-05	0.000833	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.16e-05	0.000831	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADCY5—osteoporosis	1.15e-05	0.000823	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TPI1—osteoporosis	1.14e-05	0.000822	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS2—osteoporosis	1.14e-05	0.000821	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—osteoporosis	1.12e-05	0.000804	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SPP1—osteoporosis	1.11e-05	0.000796	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—osteoporosis	1.09e-05	0.000782	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—P4HB—osteoporosis	1.08e-05	0.000773	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—osteoporosis	1.07e-05	0.000767	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GAPDH—osteoporosis	1.06e-05	0.000759	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RAP1A—osteoporosis	1.03e-05	0.000739	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS2—osteoporosis	1e-05	0.00072	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS1—osteoporosis	9.98e-06	0.000717	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—osteoporosis	9.81e-06	0.000705	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADCY5—osteoporosis	9.68e-06	0.000696	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—osteoporosis	9.61e-06	0.00069	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6R—osteoporosis	9.37e-06	0.000673	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—osteoporosis	9.37e-06	0.000673	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—osteoporosis	9.36e-06	0.000673	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—osteoporosis	9.24e-06	0.000664	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS1—osteoporosis	8.75e-06	0.000629	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—osteoporosis	8.71e-06	0.000626	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS2—osteoporosis	8.47e-06	0.000609	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—osteoporosis	8.43e-06	0.000605	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—osteoporosis	8.32e-06	0.000597	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—osteoporosis	8.29e-06	0.000596	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6R—osteoporosis	8.22e-06	0.00059	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMA2—osteoporosis	8.19e-06	0.000589	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMA5—osteoporosis	8.19e-06	0.000589	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—osteoporosis	8.1e-06	0.000582	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—osteoporosis	7.91e-06	0.000569	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS1—osteoporosis	7.4e-06	0.000531	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—osteoporosis	7.12e-06	0.000512	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—osteoporosis	7.07e-06	0.000508	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6R—osteoporosis	6.95e-06	0.000499	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—osteoporosis	6.85e-06	0.000492	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP19A1—osteoporosis	6.65e-06	0.000478	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—osteoporosis	6.2e-06	0.000445	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—osteoporosis	5.55e-06	0.000399	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—osteoporosis	5.54e-06	0.000398	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADCY5—osteoporosis	5.43e-06	0.00039	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—osteoporosis	5.41e-06	0.000389	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—osteoporosis	5.24e-06	0.000376	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—osteoporosis	5e-06	0.000359	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—osteoporosis	4.87e-06	0.00035	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—osteoporosis	4.86e-06	0.000349	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—osteoporosis	4.18e-06	0.0003	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—osteoporosis	4.12e-06	0.000296	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—osteoporosis	4.11e-06	0.000295	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—osteoporosis	4e-06	0.000287	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—osteoporosis	3.66e-06	0.000263	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—osteoporosis	3.09e-06	0.000222	CbGpPWpGaD
